Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 93 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Valvular Diseases Clear all

Conditions: Atrial Fibrillation, Deep Vein Thrombosis, Cardiac Valvular Insufficiency, Coagulopathies, Pulmonary Embolism
Interventions: Genotype-guided, Standard-of-Care; Genetic · Other
Lead sponsor: University of Puerto Rico; Other
Eligibility: 21 Years to 90 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Stroke
Interventions: Amulet Left Atrial Appendage Occluder, WATCHMAN Left Atrial Appendage Closure; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 1,878 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 85
States / cities: Huntsville, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 70 more

Conditions: Atrial Fibrillation, Stroke, Bleeding
Interventions: WATCHMAN FLX LAAC Device, Non-Vitamin K Oral Anticoagulant; Device · Drug
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 95
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 83 more

Conditions: Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency, Aortic Valve Disease
Interventions: JenaValve Trilogy Heart Valve System; Device
Lead sponsor: JenaValve Technology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 30
States / cities: Tucson, Arizona • Los Angeles, California • San Diego, California + 25 more

Conditions: Atrial Fibrillation
Interventions: Observational; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 38,499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Delirium
Interventions: Dexmedetomidine, Propofol, Midazolam; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Stanford, California

Conditions: Cardiomyopathy, Cardiovascular Diseases, Congestive Heart Failure, Coronary Artery Disease, Heart Disease, Valvular Heart Disease, Mitral Valve Disease
Interventions: Undersizing Mitral Annuloplasty, Papillary Muscle Approximation; Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Atrial Fibrillation, Medication Adherence
Interventions: Health Messaging (Non-Procedural); Other
Lead sponsor: Tammy Toscos; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Atrial Fibrillation
Interventions: Dabigatran vs. Rivaroxaban, Dabigatran vs. Apixaban; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 42,534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Atrial Fibrillation, Stroke, Embolism
Interventions: Rivaroxaban, Warfarin, Matching placebo for Rivaroxaban arm (Warfarin placebo), Matching placebo for Warfarin arm (Rivaroxaban placebo); Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 14,269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 295
States / cities: Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 292 more

Conditions: Atrial Fibrillation
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 581 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Non-valvular Atrial Fibrillation
Interventions: Alive Cor Kardia mobile electrocardiogram monitor; Device
Lead sponsor: Saint Luke's Health System; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Aortic Regurgitation, Mitral Regurgitation, Aortic Stenosis
Interventions: CMR, Quality of Life Questionnaire; Diagnostic Test · Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Atrial Fibrillation
Interventions: Apixaban, Parenteral heparin and/or oral Vitamin K antagonist; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 63
States / cities: Birmingham, Alabama • Avondale, Arizona • Chula Vista, California + 32 more

Conditions: Mitral Valve Regurgitation, Left Ventricular Dysfunction, Heart Failure, Mitral Insufficiency, Mitral Incompetence, Ischemic Heart Disease
Interventions: Percutaneous mitral valve repair; Device
Lead sponsor: Myocor; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 4
States / cities: Atlanta, Georgia • Evanston, Illinois • Shawnee Mission, Kansas + 1 more

Conditions: Atrial Fibrillation
Interventions: Apixaban, Vitamin K antagonist; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 18,591 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Stroke
Interventions: Coherex WaveCrest® Left Atrial Appendage Occlusion System, Watchman® LAA Closure Device; Device
Lead sponsor: Coherex Medical; Industry
Eligibility: 18 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 23
States / cities: Birmingham, Alabama • Chandler, Arizona • Los Angeles, California + 18 more

Conditions: Cardiovascular Diseases, Heart Failure, Ischemic Heart Disease, Non-ischemic Cardiomyopathy, Valvular Heart Disease, Metabolic Cardiomyopathy, Congenital Heart Disease, Aortic Diseases, Atrial Fibrillation, Ventricular Fibrillation
Interventions: MRI; Diagnostic Test
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2042
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Stroke
Interventions: WATCHMAN LAAC Device Implant, Single Antiplatelet Therapy or No Therapy (Control); Device · Drug
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 71
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 65 more

Conditions: Atrial Fibrillation, Left Atrial Appendage Thrombosis, CVA
Interventions: LAmbre PlusTM Left Atrial Appendage Closure System, Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa); Device · Drug
Lead sponsor: Brian O'Neill MD; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Acute Myocardial Infarction, Percutaneous Coronary Intervention, Coronary Artery Disease, Valvular Disease, Chronic Stable Angina, Chronic Stable Heart Failure
Interventions: Hospital-based CR + Movn Application, Choice of Hospital or home-based CR + Movn Application, Hospital-based CR + Movn Application + Nudge, Choice of Hospital or home-based CR + Movn Application + Nudge; Other
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years to 100 Years
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Aortic Valve Disease
Interventions: VIV TAVR with BVF using TCEP; Device
Lead sponsor: Saint Luke's Health System; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Aortic Valve Stenosis, Heart Valve Diseases, Heart Diseases, Cardiovascular Diseases, Ventricular Outflow Obstruction
Interventions: JenaValve Pericardial TAVR System; Device
Lead sponsor: JenaValve Technology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • New York, New York

Conditions: Atrial Fibrillation
Interventions: WATCHMAN FLX Implant, Market-approved OAC; Device · Drug
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 81
States / cities: Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 70 more

Search by objective public record fields.

A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics

AMPLATZER™ Amulet™ LAA Occluder Trial

CHAMPION-AF Clinical Trial

The JenaValve ALIGN-AR Pivotal Trial

The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage

Is Dexmedetomidine Associated With a Lower Incidence of Postoperative Delirium When Compared to Propofol or Midazolam in Cardiac Surgery Patients

Improving Mitral Repair for Functional Mitral Regurgitation

Keep it SIMPLE: Improving Anti-Coagulation Medication Adherence

The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis

An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation

Understanding and Improving Anticoagulation Dosing for Patients With Atrial Fibrillation

Better Outcomes for Anticoagulation Treatment Through Observation of Atrial Rhythm

Novel Characterization of Sex Specific Biologic Signatures in Valvular Heart Disease

Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

VIVID - Valvular and Ventricular Improvement Via iCoapsys Delivery - Feasibility Study

Real-world Comparative Effectiveness of Apixaban Versus Vitamin K Antagonist

WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2

Development of CIRC Technologies

Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation

Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF

Enhancing Cardiac Rehabilitation Through Behavioral Nudges

Quantification of Debris Captured Using TCEP During VIV TAVR With BVF

JENAVALVE AS EFS TRIAL: Pericardial TAVR Aortic Stenosis Study

Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation